RJA
RXST icon

Raymond James & Associates’s RxSight RXST Stock Holding History

Raymond James & Associates’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-58,988
Closed -$3.55M – 4088
2024
Q2 		$3.55M Buy
+58,988
New +$3.37M ﹤0.01% 1816

Other funds holding RXST

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James & Associates's RXST Position: Q3 2024 in Review

Raymond James & Associates sold out of RxSight (RXST) in Q3 2024, closing a stake of 58,988 shares — an estimated $3.55M sold.

Raymond James & Associates first reported a position in RXST in Q2 2024 and held it in 1 quarter. The position peaked at $3.55M in Q2 2024. 214 funds tracked by Wall St. Rank hold RXST as of Q3 2024.

  • Raymond James & Associates reported no remaining RxSight position as of Q3 2024 after selling out during the quarter.
  • Raymond James & Associates sold 58,988 RxSight shares in Q3 2024, an estimated $3.55M.
  • Raymond James & Associates first reported a position in RxSight in Q2 2024 and held it in 1 quarter.
  • Raymond James & Associates's RxSight position peaked at $3.55M in Q2 2024.
  • 214 funds tracked by Wall St. Rank held RxSight as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.